CTLA4 and neoplasm: Similar results were also found in the other tumor cohort (Figure 7(e),p = 0.0041, log-rank test) and two melanoma cohorts (Figures 7(f) and 7(g); GSE91061, anti-PD-1 cohort:p = 0.044; and PRJEB23709, anti-PD-1 and anti-CTLA4 mixed cohorts:p = 0.01; log-rank test).